Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyDuvelisib
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Duvelisib
- Accession Number
- DB11952
- Type
- Small Molecule
- Groups
- Investigational
- Description
Duvelisib has been used in trials studying the treatment and basic science of Lymphoma, Leukemia, T-cell Lymphoma, Hepatic Impairment, and Follicular Lymphoma, among others.
- Structure
Structure for DB11952 (Duvelisib)
- Synonyms
- Not Available
- External IDs
- INK-1197 / IPI-145
- Categories
- UNII
- 610V23S0JI
- CAS number
- 1201438-56-3
- Weight
- Average: 416.87
Monoisotopic: 416.1152369 - Chemical Formula
- C22H17ClN6O
- InChI Key
- SJVQHLPISAIATJ-ZDUSSCGKSA-N
- InChI
- InChI=1S/C22H17ClN6O/c1-13(28-21-19-20(25-11-24-19)26-12-27-21)17-10-14-6-5-9-16(23)18(14)22(30)29(17)15-7-3-2-4-8-15/h2-13H,1H3,(H2,24,25,26,27,28)/t13-/m0/s1
- IUPAC Name
- 8-chloro-2-phenyl-3-[(1S)-1-[(9H-purin-6-yl)amino]ethyl]-1,2-dihydroisoquinolin-1-one
- SMILES
- C[C@H](NC1=C2N=CNC2=NC=N1)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1
Pharmacology
- Indication
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Duvelisib. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when Duvelisib is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when Duvelisib is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when Duvelisib is combined with 5-androstenedione. Experimental, Illicit Abciximab Duvelisib may increase the anticoagulant activities of Abciximab. Approved Acebutolol Duvelisib may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when Duvelisib is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Duvelisib is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol Duvelisib may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Acetylsalicylic acid. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Duvelisib. Approved Alclofenac The risk or severity of adverse effects can be increased when Duvelisib is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when Duvelisib is combined with Aldosterone. Experimental, Investigational Alendronic acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Alendronic acid. Approved Aliskiren Duvelisib may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Alminoprofen. Experimental Alprenolol Duvelisib may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with Duvelisib. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when Duvelisib is combined with Amcinonide. Approved Amiloride Duvelisib may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Aminosalicylic Acid. Approved Ancrod Duvelisib may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Duvelisib. Investigational Androstenedione The risk or severity of adverse effects can be increased when Duvelisib is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when Duvelisib is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when Duvelisib is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Duvelisib. Investigational Antipyrine The risk or severity of adverse effects can be increased when Duvelisib is combined with Antipyrine. Approved, Investigational Antithrombin III human Duvelisib may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when Duvelisib is combined with Antrafenine. Approved Apixaban Duvelisib may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when Duvelisib is combined with Apocynin. Investigational Apramycin Duvelisib may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Duvelisib. Approved, Investigational Arbekacin Duvelisib may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin Duvelisib may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Duvelisib may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol Duvelisib may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine Duvelisib may decrease the antihypertensive activities of Asenapine. Approved Atamestane The risk or severity of adverse effects can be increased when Duvelisib is combined with Atamestane. Investigational Atenolol Duvelisib may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Duvelisib. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Duvelisib. Approved Azficel-T The risk or severity of adverse effects can be increased when Duvelisib is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Duvelisib. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with Duvelisib. Investigational Balsalazide The risk or severity of adverse effects can be increased when Duvelisib is combined with Balsalazide. Approved, Investigational Becaplermin Duvelisib may increase the anticoagulant activities of Becaplermin. Approved, Investigational Befunolol Duvelisib may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin Duvelisib may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when Duvelisib is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when Duvelisib is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Duvelisib. Approved Benorilate The risk or severity of adverse effects can be increased when Duvelisib is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Duvelisib. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with Duvelisib. Approved Benzydamine The risk or severity of adverse effects can be increased when Duvelisib is combined with Benzydamine. Approved Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with Duvelisib. Investigational Betamethasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Betamethasone. Approved, Vet Approved Betaxolol Duvelisib may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Duvelisib. Approved, Investigational Bevantolol Duvelisib may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when Duvelisib is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with Duvelisib. Approved, Investigational Bisoprolol Duvelisib may decrease the antihypertensive activities of Bisoprolol. Approved Bivalirudin Duvelisib may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bopindolol Duvelisib may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when Duvelisib is combined with Bromfenac. Approved Bucillamine The risk or severity of adverse effects can be increased when Duvelisib is combined with Bucillamine. Investigational Bucindolol Duvelisib may decrease the antihypertensive activities of Bucindolol. Investigational Bufexamac The risk or severity of adverse effects can be increased when Duvelisib is combined with Bufexamac. Approved, Experimental Bufuralol Duvelisib may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when Duvelisib is combined with Bumadizone. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with Duvelisib. Approved Bupranolol Duvelisib may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with Duvelisib. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Duvelisib. Approved Candoxatril The risk or severity of adverse effects can be increased when Duvelisib is combined with Candoxatril. Experimental Capsaicin The risk or severity of adverse effects can be increased when Duvelisib is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when Duvelisib is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Duvelisib is combined with Carbaspirin calcium. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Duvelisib. Approved Carprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Carprofen. Approved, Vet Approved, Withdrawn Carteolol Duvelisib may decrease the antihypertensive activities of Carteolol. Approved Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Duvelisib. Experimental Celecoxib The risk or severity of adverse effects can be increased when Duvelisib is combined with Celecoxib. Approved, Investigational Celiprolol Duvelisib may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin Duvelisib may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Duvelisib. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Duvelisib. Approved, Vet Approved Chlorphenesin The risk or severity of adverse effects can be increased when Duvelisib is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Duvelisib. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Duvelisib is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when Duvelisib is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when Duvelisib is combined with Cilazapril. Approved Cimicoxib The risk or severity of adverse effects can be increased when Duvelisib is combined with Cimicoxib. Investigational Cinoxacin Duvelisib may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Cisplatin The risk or severity of adverse effects can be increased when Duvelisib is combined with Cisplatin. Approved Clobetasol The risk or severity of adverse effects can be increased when Duvelisib is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when Duvelisib is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when Duvelisib is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Duvelisib. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with Duvelisib. Vet Approved Cloranolol Duvelisib may decrease the antihypertensive activities of Cloranolol. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Duvelisib resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when Duvelisib is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when Duvelisib is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when Duvelisib is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Duvelisib. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Duvelisib. Experimental Dabigatran etexilate Duvelisib may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Duvelisib may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Duvelisib may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Duvelisib may increase the anticoagulant activities of Darexaban. Investigational Deferasirox The risk or severity of adverse effects can be increased when Duvelisib is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when Duvelisib is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when Duvelisib is combined with Delapril. Investigational Desipramine Duvelisib may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin Duvelisib may increase the anticoagulant activities of Desirudin. Approved Desmopressin The risk or severity of adverse effects can be increased when Duvelisib is combined with Desmopressin. Approved Desonide The risk or severity of adverse effects can be increased when Duvelisib is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when Duvelisib is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when Duvelisib is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when Duvelisib is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Duvelisib. Approved, Investigational Dextran Duvelisib may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dibekacin Duvelisib may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when Duvelisib is combined with Dibotermin alfa. Approved, Investigational Dicoumarol Duvelisib may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when Duvelisib is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when Duvelisib is combined with Diflunisal. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when Duvelisib is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when Duvelisib is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Duvelisib. Approved Dihydrostreptomycin Duvelisib may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with Duvelisib. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Duvelisib. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with Duvelisib. Approved Drospirenone Duvelisib may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when Duvelisib is combined with Droxicam. Withdrawn E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Duvelisib. Investigational Edetic Acid Duvelisib may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Duvelisib may increase the anticoagulant activities of Edoxaban. Approved Enalapril The risk or severity of adverse effects can be increased when Duvelisib is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Duvelisib is combined with Enalaprilat. Approved Enoxacin Duvelisib may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin Duvelisib may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with Duvelisib. Experimental Epanolol Duvelisib may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Duvelisib. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with Duvelisib. Experimental Eplerenone Duvelisib may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Duvelisib. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with Duvelisib. Approved Equilenin The risk or severity of adverse effects can be increased when Duvelisib is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when Duvelisib is combined with Equilin. Approved Esatenolol Duvelisib may decrease the antihypertensive activities of Esatenolol. Experimental Esmolol Duvelisib may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when Duvelisib is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when Duvelisib is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Duvelisib. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Duvelisib is combined with Etanercept. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Duvelisib is combined with Ethenzamide. Experimental Ethyl biscoumacetate Duvelisib may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when Duvelisib is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Duvelisib. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Duvelisib is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Duvelisib. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Duvelisib. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Duvelisib. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Duvelisib. Approved Fenoprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Fenoprofen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with Duvelisib. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Duvelisib is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when Duvelisib is combined with Feprazone. Experimental Ferulic acid Duvelisib may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with Duvelisib. Approved, Investigational Fleroxacin Duvelisib may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Duvelisib. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when Duvelisib is combined with Fludrocortisone. Approved, Investigational Fluindione Duvelisib may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine Duvelisib may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when Duvelisib is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Duvelisib. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with Duvelisib. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when Duvelisib is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Flurbiprofen. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when Duvelisib is combined with Fluticasone furoate. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with Duvelisib. Approved, Nutraceutical, Vet Approved Fondaparinux Duvelisib may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with Duvelisib. Experimental Formestane The risk or severity of adverse effects can be increased when Duvelisib is combined with Formestane. Approved, Investigational, Withdrawn Framycetin Duvelisib may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Gabexate Duvelisib may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin Duvelisib may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin Duvelisib may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with Duvelisib. Approved, Withdrawn Gemifloxacin Duvelisib may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin Duvelisib may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin Duvelisib may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A Duvelisib may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginseng The risk or severity of adverse effects can be increased when Duvelisib is combined with Ginseng. Approved, Investigational, Nutraceutical Grepafloxacin Duvelisib may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Duvelisib is combined with Guacetisal. Experimental Halcinonide The risk or severity of adverse effects can be increased when Duvelisib is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when Duvelisib is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when Duvelisib is combined with HE3286. Investigational Heparin Duvelisib may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when Duvelisib is combined with Higenamine. Investigational Hydralazine Duvelisib may decrease the antihypertensive activities of Hydralazine. Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Duvelisib. Approved, Investigational Hygromycin B Duvelisib may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Duvelisib. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Duvelisib. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when Duvelisib is combined with Icosapent. Approved, Nutraceutical Idraparinux Duvelisib may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with Duvelisib. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Duvelisib is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when Duvelisib is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with Duvelisib. Approved Indenolol Duvelisib may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when Duvelisib is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when Duvelisib is combined with Indomethacin. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Duvelisib. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with Duvelisib. Approved, Investigational Isepamicin Duvelisib may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Duvelisib. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when Duvelisib is combined with Istaroxime. Investigational Kanamycin Duvelisib may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Duvelisib. Experimental Ketoprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Ketoprofen. Approved, Vet Approved Landiolol Duvelisib may decrease the antihypertensive activities of Landiolol. Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Duvelisib. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Duvelisib. Approved, Investigational Lepirudin Duvelisib may increase the anticoagulant activities of Lepirudin. Approved Letaxaban Duvelisib may increase the anticoagulant activities of Letaxaban. Investigational Levobetaxolol Duvelisib may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol Duvelisib may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin Duvelisib may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with Duvelisib. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Duvelisib is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Duvelisib is combined with Lisofylline. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with Duvelisib. Experimental Lomefloxacin Duvelisib may increase the neuroexcitatory activities of Lomefloxacin. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when Duvelisib is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when Duvelisib is combined with Lornoxicam. Approved, Investigational Loteprednol The risk or severity of adverse effects can be increased when Duvelisib is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Duvelisib. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Duvelisib. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when Duvelisib is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with Duvelisib. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when Duvelisib is combined with Magnesium salicylate. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Duvelisib. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when Duvelisib is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Meclofenamic acid. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when Duvelisib is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Mefenamic acid. Approved Melagatran Duvelisib may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when Duvelisib is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when Duvelisib is combined with Meloxicam. Approved, Vet Approved Mepindolol Duvelisib may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine The risk or severity of adverse effects can be increased when Duvelisib is combined with Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Duvelisib. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with Duvelisib. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Duvelisib. Approved Metipranolol Duvelisib may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with Duvelisib. Approved Micronomicin Duvelisib may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Duvelisib. Approved, Experimental Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with Duvelisib. Approved Mizoribine The risk or severity of adverse effects can be increased when Duvelisib is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when Duvelisib is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when Duvelisib is combined with Mofebutazone. Experimental Mometasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with Duvelisib. Approved Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Duvelisib. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Duvelisib. Approved Nabumetone The risk or severity of adverse effects can be increased when Duvelisib is combined with Nabumetone. Approved Nadolol Duvelisib may decrease the antihypertensive activities of Nadolol. Approved Nadroparin Duvelisib may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Duvelisib may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Duvelisib. Approved Nalidixic Acid Duvelisib may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational NCX 1022 The risk or severity of adverse effects can be increased when Duvelisib is combined with NCX 1022. Investigational Neamine Duvelisib may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol Duvelisib may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin Duvelisib may increase the neuroexcitatory activities of Nemonoxacin. Investigational Nepafenac The risk or severity of adverse effects can be increased when Duvelisib is combined with Nepafenac. Approved, Investigational Netilmicin Duvelisib may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Duvelisib is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Niflumic Acid. Approved Nitroaspirin The risk or severity of adverse effects can be increased when Duvelisib is combined with Nitroaspirin. Investigational Norfloxacin Duvelisib may increase the neuroexcitatory activities of Norfloxacin. Approved Ofloxacin Duvelisib may increase the neuroexcitatory activities of Ofloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when Duvelisib is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with Duvelisib. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Duvelisib. Approved Olsalazine Duvelisib may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when Duvelisib is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when Duvelisib is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Duvelisib. Vet Approved Otamixaban Duvelisib may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when Duvelisib is combined with Oxaprozin. Approved Oxolinic acid Duvelisib may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol Duvelisib may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Duvelisib. Approved, Withdrawn Palmidrol The risk or severity of adverse effects can be increased when Duvelisib is combined with Palmidrol. Experimental, Nutraceutical Pamidronate The risk or severity of adverse effects can be increased when Duvelisib is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when Duvelisib is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when Duvelisib is combined with Parecoxib. Approved Parthenolide The risk or severity of adverse effects can be increased when Duvelisib is combined with Parthenolide. Approved, Investigational Pazufloxacin Duvelisib may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin Duvelisib may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol Duvelisib may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Duvelisib may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate Duvelisib may increase the anticoagulant activities of Pentosan Polysulfate. Approved Perindopril The risk or severity of adverse effects can be increased when Duvelisib is combined with Perindopril. Approved Phenindione Duvelisib may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon Duvelisib may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when Duvelisib is combined with Phenylbutazone. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Duvelisib. Approved, Investigational Pindolol Duvelisib may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid Duvelisib may increase the neuroexcitatory activities of Pipemidic acid. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with Duvelisib. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Duvelisib. Approved, Investigational Piromidic acid Duvelisib may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Duvelisib is combined with Piroxicam. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Pirprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when Duvelisib is combined with Pitolisant. Approved, Investigational Platelet Activating Factor Duvelisib may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin Duvelisib may decrease the excretion rate of Plazomicin which could result in a higher serum level. Approved, Investigational Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with Duvelisib. Approved Pomalidomide The risk or severity of adverse effects can be increased when Duvelisib is combined with Pomalidomide. Approved Potassium Citrate Duvelisib may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol Duvelisib may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with Duvelisib. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Pranoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when Duvelisib is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when Duvelisib is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when Duvelisib is combined with Prednicarbate. Approved, Investigational Prednisone The risk or severity of adverse effects can be increased when Duvelisib is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when Duvelisib is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of Duvelisib can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when Duvelisib is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Duvelisib. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Duvelisib is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when Duvelisib is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Duvelisib. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Duvelisib. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with Duvelisib. Vet Approved Protein C Duvelisib may increase the anticoagulant activities of Protein C. Approved Protein S human Duvelisib may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Duvelisib may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin Duvelisib may increase the neuroexcitatory activities of Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Duvelisib. Investigational Puromycin Duvelisib may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when Duvelisib is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with Duvelisib. Approved Ramipril The risk or severity of adverse effects can be increased when Duvelisib is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when Duvelisib is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when Duvelisib is combined with Resveratrol. Approved, Experimental, Investigational Reviparin Duvelisib may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin Duvelisib may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when Duvelisib is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when Duvelisib is combined with Risedronate. Approved, Investigational Rivaroxaban Duvelisib may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when Duvelisib is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin Duvelisib may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin Duvelisib may increase the neuroexcitatory activities of Rufloxacin. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with Duvelisib. Approved Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Duvelisib. Approved Salsalate The risk or severity of adverse effects can be increased when Duvelisib is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with Duvelisib. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with Duvelisib. Investigational Seliciclib The risk or severity of adverse effects can be increased when Duvelisib is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when Duvelisib is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Duvelisib. Approved Serrapeptase The risk or severity of adverse effects can be increased when Duvelisib is combined with Serrapeptase. Investigational Sisomicin Duvelisib may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin Duvelisib may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sotalol Duvelisib may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin Duvelisib may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when Duvelisib is combined with Spirapril. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Duvelisib. Investigational Streptomycin Duvelisib may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Sulodexide Duvelisib may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with Duvelisib. Investigational Suprofen The risk or severity of adverse effects can be increased when Duvelisib is combined with Suprofen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Duvelisib is combined with Suxibuzone. Experimental Tacrolimus Duvelisib may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with Duvelisib. Approved Talinolol Duvelisib may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with Duvelisib. Approved Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Duvelisib. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with Duvelisib. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when Duvelisib is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when Duvelisib is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with Duvelisib. Approved, Investigational Temafloxacin Duvelisib may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when Duvelisib is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when Duvelisib is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when Duvelisib is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when Duvelisib is combined with Tenoxicam. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Duvelisib. Vet Approved Terbutaline Duvelisib may decrease the antihypertensive activities of Terbutaline. Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Duvelisib. Approved Tertatolol Duvelisib may decrease the antihypertensive activities of Tertatolol. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Tiaprofenic acid. Approved Tiludronic acid The risk or severity of adverse effects can be increased when Duvelisib is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol Duvelisib may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when Duvelisib is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when Duvelisib is combined with Tixocortol. Approved, Withdrawn Tobramycin Duvelisib may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Duvelisib is combined with Tolmetin. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with Duvelisib. Approved Trandolapril The risk or severity of adverse effects can be increased when Duvelisib is combined with Trandolapril. Approved Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with Duvelisib. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with Duvelisib. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when Duvelisib is combined with Triamcinolone. Approved, Vet Approved Triamterene Duvelisib may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when Duvelisib is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Duvelisib. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Duvelisib is combined with Triptolide. Investigational Trovafloxacin Duvelisib may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin Duvelisib may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when Duvelisib is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with Duvelisib. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when Duvelisib is combined with Valdecoxib. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with Duvelisib. Approved, Investigational Warfarin Duvelisib may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Duvelisib may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Duvelisib. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Duvelisib. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when Duvelisib is combined with Zofenopril. Experimental Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Duvelisib. Withdrawn - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0195 mg/mL ALOGPS logP 3.91 ALOGPS logP 3.67 ChemAxon logS -4.3 ALOGPS pKa (Strongest Acidic) 9.86 ChemAxon pKa (Strongest Basic) 3.99 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 86.8 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 118.53 m3·mol-1 ChemAxon Polarizability 42.2 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as isoquinolones and derivatives. These are aromatic polycyclic compounds containing a ketone bearing isoquinoline moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Isoquinolines and derivatives
- Sub Class
- Isoquinolones and derivatives
- Direct Parent
- Isoquinolones and derivatives
- Alternative Parents
- 6-alkylaminopurines / Secondary alkylarylamines / Pyridinones / Aminopyrimidines and derivatives / Aryl chlorides / Benzene and substituted derivatives / Imidolactams / Vinylogous halides / Imidazoles / Heteroaromatic compounds show 7 more
- Substituents
- Isoquinolone / 6-alkylaminopurine / 6-aminopurine / Imidazopyrimidine / Purine / Aminopyrimidine / Pyridinone / Secondary aliphatic/aromatic amine / Aryl chloride / Aryl halide show 23 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
Drug created on October 20, 2016 15:04 / Updated on August 02, 2018 06:31